Last reviewed · How we verify
Insulin, sulfonylurea
This combination therapy uses insulin to provide exogenous glucose control while sulfonylureas stimulate endogenous insulin secretion from pancreatic beta cells.
This combination therapy uses insulin to provide exogenous glucose control while sulfonylureas stimulate endogenous insulin secretion from pancreatic beta cells. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin, sulfonylurea |
|---|---|
| Sponsor | University of Pittsburgh |
| Drug class | Insulin + Sulfonylurea combination |
| Target | Insulin receptor (insulin component); ATP-sensitive potassium channel (sulfonylurea component) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin directly lowers blood glucose by promoting cellular uptake and utilization of glucose, while sulfonylureas bind to ATP-sensitive potassium channels on beta cells, triggering insulin release. Together, they address both insulin deficiency and insulin secretion capacity in type 2 diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Gastrointestinal disturbances
Key clinical trials
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
- Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes (PHASE3)
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM (PHASE4)
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin, sulfonylurea CI brief — competitive landscape report
- Insulin, sulfonylurea updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI